现代医药卫生2024,Vol.40Issue(17) :3033-3036,3048.DOI:10.3969/j.issn.1009-5519.2024.17.033

脂联素与衰弱相关性的研究进展

Research progress on the correlation between adiponectin and frailty

王梓祎 潘建鑫
现代医药卫生2024,Vol.40Issue(17) :3033-3036,3048.DOI:10.3969/j.issn.1009-5519.2024.17.033

脂联素与衰弱相关性的研究进展

Research progress on the correlation between adiponectin and frailty

王梓祎 1潘建鑫1
扫码查看

作者信息

  • 1. 重庆医科大学附属大学城医院全科医学科,重庆 401331
  • 折叠

摘要

衰弱作为一种与增龄相关的老年综合征,已成为威胁老年人健康的重要社会问题,对衰弱的早期识别和干预有助于减少其导致的临床负性事件的发生,对提高老年人患者生活质量、预防过早死亡和延长期望寿命具有重要意义.脂联素作为一种具有多种生理作用的脂肪细胞因子,有可能成为衰弱的潜在生物标志物.该文对脂联素与老年人衰弱的相关性研究进展进行了综述,旨在为脂联素作为衰弱生物标志物及后续相关治疗药物研发提供参考依据.

Abstract

As an age-related geriatric syndrome,frailty has become an important social problem that threatens the health of the elderly.Early identification and intervention of frailty can help reduce the occur-rence of clinical negative events caused by frailty.It is of great significance to improve the quality of life of eld-erly patients,prevent premature death and prolong life expectancy.Adiponectin,as an adipocytokine with a va-riety of physiological effects,may become a potential biomarker for frailty.This article reviews the research on the correlation between adiponectin and frailty in the elderly,aiming to provide a reference for the develop-ment of adiponectin as a biomarker of frailty and subsequent related therapeutic drugs.

关键词

脂联素/衰弱/生物标志物/早期识别/综述

Key words

Adiponectin/Frailty/Biomarkers/Early identification/Review

引用本文复制引用

出版年

2024
现代医药卫生
重庆市卫生信息中心

现代医药卫生

影响因子:0.758
ISSN:1009-5519
段落导航相关论文